JosÃ© Baselga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7832584/publications.pdf

Version: 2024-02-01

160 papers	46,733 citations	78 h-index	158 g-index
		7096	6300
162 all docs	162 docs citations	162 times ranked	47876 citing authors

#	Article	IF	Citations
1	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. British Journal of Cancer, 2021, 125, 38-47.	6.4	4
2	Cell Lineâ€“Specific Network Models of ER+ Breast Cancer Identify Potential PI3KÎ± Inhibitor Resistance Mechanisms and Drug Combinations. Cancer Research, 2021, 81, 4603-4617.	0.9	13
3	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Npj Breast Cancer, 2021, 7, 145.	5.2	9
4	Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clinical Breast Cancer, 2020, 20, 174-181.e3.	2.4	5
5	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell, 2020, 38, 534-550.e9.	16.8	67
6	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunology, 2020, 5, .	11.9	304
7	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics, 2020, 52, 198-207.	21.4	140
8	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	9.4	83
9	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients withAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 3947-3957.	7.0	54
10	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 1226-1238.	10.7	76
11	Survival outcomes of the NeoALTTO study (BIG 1â€“06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. European Journal of Cancer, 2019, 118, 169-177.	2.8	51
12	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	27.8	295
13	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3KÎ± inhibitors. Science, 2019, 366, 714-723.	12.6	185
14	PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. Cell Reports, 2019, 27, 294-306.e5.	6.4	49
15	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	27.8	1,391
16	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology, 2019, 32, 81-87.	5.5	10
17	Next-Generation Sequencingâ€“Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	2.8	19
18	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702

#	Article	IF	Citations
19	Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptorâ€“Positive Advanced Breast Cancer. JAMA Oncology, 2019, 5, e184475.	7.1	187
20	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572
21	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	9.4	275
22	BRAF Inhibition in BRAF^{V600}-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	1.6	247
23	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	1.6	381
24	Phosphatidylinositol 3-Kinase Î±â€“Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology, 2018, 36, 1291-1299.	1.6	298
25	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology, 2018, 36, 3126-3133.	1.6	52
26	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	3.0	20
27	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	16.8	307
28	p95HER2â€“T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	12.4	59
29	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	3.6	53
30	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. EMBO Molecular Medicine, 2018, 10, .	6.9	169
31	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. European Journal of Cancer, 2018, 103, 147-154.	2.8	52
32	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
33	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptorâ€“Positive Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 4380-4387.	7.0	49
34	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	21.4	411
35	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	7.1	139
36	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. JAMA Oncology, 2018, 4, e181564.	7.1	13

#	Article	IF	Citations
37	Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors. Cancer Research, 2018, 78, CT046-CT046.	0.9	4
38	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. Blood, 2018, 132, 747-747.	1.4	3
39	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology, 2018, 36, LBA1006-LBA1006.	1.6	116
40	Implementing Genome-Driven Oncology. Cell, 2017, 168, 584-599.	28.9	405
41	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2â^' advanced breast cancer: results from BOLERO-2. British Journal of Cancer, 2017, 116, 726-730.	6.4	112
42	Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nature Communications, 2017, 8, 14292.	12.8	90
43	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
44	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 904-916.	10.7	427
45	PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science, 2017, 355, 1324-1330.	12.6	217
46	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	9.4	490
47	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334.	7.0	64
48	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research, 2017, 23, 3053-3060.	7.0	66
49	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	2.8	96
50	Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discovery, 2017, 7, 277-287.	9.4	286
51	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.9	58
52	Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology, 2017, 119, 113-122.	4.4	42
53	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	11.1	578
54	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature, 2017, 547, 109-113.	27.8	142

#	Article	IF	Citations
55	Recurrent and functional regulatory mutations in breast cancer. Nature, 2017, 547, 55-60.	27.8	269
56	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. JAMA Oncology, 2017, 3, 227.	7.1	118
57	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discovery, 2017, 7, 102-113.	9.4	136
58	AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology, 2017, 35, 2251-2259.	1.6	240
59	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
60	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102
61	Stratification and therapeutic potential of PML in metastatic breast cancer. Nature Communications, 2016, 7, 12595.	12.8	45
62	The hVps34â€•<scp>SGK</scp> 3 pathway alleviates sustained PI3K/Akt inhibition by stimulating <scp>mTORC</scp> 1 and tumourÂgrowth. EMBO Journal, 2016, 35, 1902-1922.	7.8	77
63	Somatic PIK3CA mutations as a driver of sporadic venous malformations. Science Translational Medicine, 2016, 8, 332ra42.	12.4	147
64	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptorâ€“Positive Breast Cancer. Cancer Research, 2016, 76, 2301-2313.	0.9	509
65	Therapeutic Benefit of Selective Inhibition of p110Î± PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5805-5817.	7.0	35
66	Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of Nuclear Medicine, 2016, 57, 1413-1419.	5.0	28
67	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports, 2016, 17, 2367-2381.	6.4	215
68	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discovery, 2016, 6, 1134-1147.	9.4	106
69	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	28.9	376
70	PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3KÎ± Inhibition. Cancer Cell, 2016, 30, 229-242.	16.8	187
71	P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science Translational Medicine, 2016, 8, 345ra87.	12.4	152
72	Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clinical Cancer Research, 2016, 22, 1313-1317.	7.0	92

#	Article	IF	Citations
73	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
74	Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing ActivatingPIK3CAAlterations. Clinical Cancer Research, 2016, 22, 2009-2019.	7.0	70
75	AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70.		49
76	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer, 2016, 16, 87-94.	2.4	1
77	Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3030-3035.	7.1	52
78	Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors. Clinical Cancer Research, 2016, 22, 2099-2101.	7.0	19
79	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology, 2016, 34, 419-426.	1.6	203
80	Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. Blood, 2016, 128, 37-37.	1.4	16
81	SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.. Journal of Clinical Oncology, 2016, 34, TPS617-TPS617.	1.6	5
82	The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. ELife, 2016, 5, e12034.	6.0	19
83	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clinical Cancer Research, 2015, 21, 2462-2470.	7.0	51
84	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	7.0	71
85	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. Methods, 2015, 77-78, 25-30.	3.8	16
86	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptorâ€“positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	12.4	276
87	First-in-Human Dose Study of the Novel Transforming Growth Factor-Î² Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clinical Cancer Research, 2015, 21, 553-560.	7.0	199
88	AXL Mediates Resistance to PI3KÎ± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546.	16.8	263
89	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted byTP53Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	7.0	18
90	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	9.4	821

#	Article	IF	Citations
91	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	6.4	136
92	Feedback Suppression of PI3KÎ± Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3KÎ². Cancer Cell, 2015, 27, 109-122.	16.8	203
93	Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71.	9.4	115
94	Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor. Nature, 2015, 518, 240-244.	27.8	486
95	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research, 2015, 21, 49-59.	7.0	49
96	Abstract CT330: Phase I study of PI3KÎ± inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). Cancer Research, 2015, 75, CT330-CT330.	0.9	3
97	Abstract PD5-5: Phase I study of the PI3KÎ± inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer. Cancer Research, 2015, 75, PD5-5-PD5-5.	0.9	11
98	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	1.4	0
99	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	178
100	Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive, First-Line Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3753-3761.	1.6	296
101	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	6.3	36
102	A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases. Clinical Cancer Research, 2014, 20, 2793-2804.	7.0	31
103	Potential biomarkers of longâ€term benefit from singleâ€agent trastuzumab or lapatinib in HER2â€positive metastatic breast cancer. Molecular Oncology, 2014, 8, 20-26.	4.6	37
104	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3626-3633.	1.6	118
105	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics, 2013, 45, 1439-1445.	21.4	960
106	Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Journal of Geriatric Oncology, 2013, 4, 346-352.	1.0	7
107	Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence. Cancer Research, 2013, 73, 450-458.	0.9	76
108	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation. Cancer Discovery, 2013, 3, 1238-1244.	9.4	43

#	Article	IF	Citations
109	Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.. Cancer Research, 2013, 73, LB-64-LB-64.	0.9	26
110	Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ÂŸ) receptor I kinase inhibitor, LY2157299 monohydrate (LY).. Journal of Clinical Oncology, 2013, 31, 2016-2016.	1.6	12
111	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 553-553.	1.6	2
112	Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 558-558.	1.6	4
113	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. Clinical Cancer Research, 2012, 18, 6364-6372.	7.0	14
114	Case 16-2012. New England Journal of Medicine, 2012, 366, 2018-2026.	27.0	6
115	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2012, 379, 633-640.	13.7	1,165
116	Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1484-1491.	1.6	151
117	Everolimus in Postmenopausal Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 366, 520-529.	27.0	2,474
118	Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 2012, 486, 405-409.	27.8	1,107
119	Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 1009-1009.	1.6	6
120	SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2012, 30, 1011-1011.	1.6	5
121	The oral transforming growth factor-beta (TGF-ÂŸ) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.. Journal of Clinical Oncology, 2012, 30, 2042-2042.	1.6	5
122	A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. Journal of Clinical Oncology, 2012, 30, 2568-2568.	1.6	9
123	A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.. Journal of Clinical Oncology, 2012, 30, 508-508.	1.6	18
124	Phase Ib combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2012, 30, TPS3118-TPS3118.	1.6	5
125	Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology, 2012, 30, 102-102.	1.6	2
126	BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. Journal of Clinical Oncology, 2012, 30, 125-125.	1.6	4

#	Article	IF	Citations
127	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology, 2012, 30, 99-99.	1.6	2
128	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 2567-2567.	1.6	1
129	Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer. Oncologist, 2011, 16, 12-19.	3.7	221
130	p95HER2 and Breast Cancer. Cancer Research, 2011, 71, 1515-1519.	0.9	195
131	A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers. Cancer Research, 2010, 70, 8537-8546.	0.9	47
132	Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research, 2010, 16, 4876-4883.	7.0	99
133	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. Journal of Clinical Oncology, 2010, 28, 1138-1144.	1.6	593
134	CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 489-491.	2.4	128
135	Reply to S.M. Ali et al. Journal of Clinical Oncology, 2009, 27, e274-e275.	1.6	1
136	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2630-2637.	1.6	582
137	A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. Molecular and Cellular Biology, 2009, 29, 3319-3331.	2.3	150
138	Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer. Journal of Clinical Oncology, 2009, 27, 526-534.	1.6	102
139	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 2009, 9, 463-475.	28.4	993
140	TGF-Î² signalling-related markers in cancer patients with bone metastasis. Biomarkers, 2008, 13, 217-236.	1.9	60
141	Creating a stronger front against cancer: ESMO and ECCO join forces. Annals of Oncology, 2008, 19, 1367-1368.	1.2	4
142	Targeting Tyrosine Kinases in Cancer: The Second Wave. Science, 2006, 312, 1175-1178.	12.6	437
143	Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer. Oncologist, 2006, 11, 4-12.	3.7	198
144	Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer. Journal of Clinical Oncology, 2005, 23, 5323-5333.	1.6	334

#	Article	IF	Citations
145	Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2005, 23, 5568-5577.	1.6	473
146	Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?. Nature Clinical Practice Oncology, 2005, 2, 284-285.	4.3	10
147	Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. Journal of Clinical Oncology, 2005, 23, 2445-2459.	1.6	676
148	Epidermal growth factor receptor pathway inhibitors. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 205-223.	0.5	14
149	Focus on breast cancer. Cancer Cell, 2002, 1, 319-322.	16.8	84
150	A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell, 2002, 2, 93-95.	16.8	48
151	Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy. Oncologist, 2002, 7, 2-8.	3.7	28
152	Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 2001, 344, 783-792.	27.0	10,216
153	Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. Oncologist, 2001, 6, 26-29.	3.7	25
154	Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. Oncologist, 2001, 6, 26-29.	3.7	1
155	The EGF receptor family as targets for cancer therapy. Oncogene, 2000, 19, 6550-6565.	5.9	1,251
156	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. Oncogene, 1998, 17, 761-767.	5.9	31
157	Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel. Cancer Investigation, 1998, 16, 67-71.	1.3	9
158	Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. , 1997, 80, 1966-1972.		221
159	Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy. Cancer, 1993, 71, 2332-2334.	4.1	21
160	A phase II trial of PALA+dipyridamole in patients with advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology, 1991, 28, 51-54.	2.3	11